Next-generation sequencing in drug development: target identification and genetically stratified clinical trials

Drug Discovery Today
Abolfazl Doostparast Torshizi, Kai Wang

Abstract

Next-generation sequencing (NGS) enabled high-throughput analysis of genotype-phenotype relationships on human populations, ushering in a new era of genetics-informed drug development. The year 2017 was remarkable, with the first FDA-approved gene therapy for cancer (Kymriah™) and for inherited diseases (LUXTURNA™), the first multiplex NGS panel for companion diagnostics (MSK-IMPACT™) and the first drug targeting a genetic signature rather than a disease (Keytruda®). We envision that population-scale NGS with paired electronic health records (EHRs) will become a routine measure in the drug development process for the identification of novel drug targets, and that genetically stratified clinical trials could be widely adopted to improve power in precision-medicine-guided drug development.

Citations

Nov 28, 2019·Briefings in Bioinformatics·Jussi Paananen, Vittorio Fortino
Mar 27, 2020·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Kurt D ChristensenUNKNOWN REVEAL Study Group
Feb 5, 2019·Technology·Paulina KrzyszczykMartin L Yarmush
Aug 14, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Bing-Ze LinYi-Jang Lee
Oct 16, 2020·Drug Discovery Today·Bertil Schmidt, Andreas Hildebrandt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Related Papers

Chemical Record : an Official Publication of the Chemical Society of Japan ... [et Al.]
Brian Johnson
The Journal of Clinical Endocrinology and Metabolism
Marina N NikiforovaYuri E Nikiforov
© 2022 Meta ULC. All rights reserved